Koenig v. Purdue Pharma Co.

435 F. Supp. 2d 551, 2006 U.S. Dist. LEXIS 38412, 2006 WL 1489250
CourtDistrict Court, N.D. Texas
DecidedMay 25, 2006
Docket3:04-CV-01590K
StatusPublished
Cited by8 cases

This text of 435 F. Supp. 2d 551 (Koenig v. Purdue Pharma Co.) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Koenig v. Purdue Pharma Co., 435 F. Supp. 2d 551, 2006 U.S. Dist. LEXIS 38412, 2006 WL 1489250 (N.D. Tex. 2006).

Opinion

MEMORANDUM OPINION and ORDER

KINKEADE, District Judge.

Before the Court is Defendants Purdue Pharma L.P. (Individually and as succes *553 sor to The Purdue Pharma Company), Purdue Pharma Inc., and the Purdue Frederick Company’s (collectively “Purdue”) motion for summary judgment. Also before the Court is Abbott Laboratories and Abbott Laboratories, Inc.’s (collectively “Abbott”) motion for summary judgment. The Court GRANTS summary judgment for Abbott and Purdue on Plaintiffs’ claims for strict products liability (Count I); breach of the implied warranty of merchantability (Count III); negligence (Count IV); and fraud, misrepresentation and suppression (Count VI) because Plaintiffs have not raised a genuine issue of material fact as to causation, an essential element of Plaintiffs’ claims. Because Plaintiffs’ underlying personal injury claims fail for lack of causation, the Court also GRANTS summary judgment for Abbott and Purdue on Plaintiffs’ derivative claims for civil conspiracy (Count VII) and loss of consortium (Count VIII). Abbott and Purdue’s motions for summary judgment are therefore GRANTED. Abbott’s motion to Strike Plaintiffs’ Exhibit 19 in support of Plaintiffs’ opposition to summary judgment is DENIED. All pending motions in limine are DENIED as moot.

I.Background Facts

This case arises out of a joint promotional marketing campaign between Purdue and Abbott. The purpose of the marketing campaign was to promote the prescription medication OxyContin Tablets (“OxyContin”), a Schedule II controlled substance opioid medication. Plaintiffs allege that the promotional marketing campaign failed to adequately warn doctors about the addiction risks of OxyContin and affirmatively misrepresented and minimized those risks in order to increase Oxy-Contin sales. Plaintiffs further allege that Koenig was prescribed OxyContin by his doctors, became addicted, and suffered adverse health affects from taking the drug.

II. Summary Judgment Legal Standard

Summary judgment is appropriate when the pleadings, affidavits and other summary judgment evidence show that no genuine issue of material fact exists and the moving party is entitled to judgment as a matter of law. Fed. R. Civ. P. 56(c); Celo-tex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). The moving party bears the burden of identifying those portions of the record it believes demonstrate the absence of a genuine issue of material fact. Celotex, 477 U.S. at 322-25, 106 S.Ct. 2548. Once a movant makes a properly supported motion, the burden shifts to the nonmovant to show that summary judgment should not be granted; the nonmovant may not rest upon allegations in the pleadings, but must support the response to the motion with summary judgment evidence showing the existence of a genuine fact issue for trial. Id. at 321-25, 106 S.Ct. 2548; Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255-57, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). All evidence and reasonable inferences must be viewed in the light most favorable to the nonmovant. United States v. Diebold, Inc., 369 U.S. 654, 655, 82 S.Ct. 993, 8 L.Ed.2d 176 (1962).

III. Koenig’s Personal Injury Claims Against Abbott

A. Causation is an Essential Element

The Court GRANTS summary judgment for Abbott on Plaintiffs’ personal injury claims because Plaintiffs have produced no evidence showing a causal connection between Abbott’s co-promotion of OxyContin and Koenig’s injuries. Causation is an essential element for each of Koenig’s personal injury claims. See Union Pump Co. v. Allbritton, 898 S.W.2d 773, 775 (Tex.1995) (strict liability); Hyundai Motor Co. v. Rodriguez, 995 S.W.2d *554 661, 667 (Tex.1999) (breach of warranty); General Motors Corp. v. Saenz, 873 S.W.2d 353, 357 (Tex.1993) (negligence); Formosa Plastics Corp. USA v. Presidio Engineers & Contractors, Inc., 960 S.W.2d 41, 47 (Tex.1998) (fraud and fraudulent concealment); Harco Energy, Inc. v. ReEntry People, Inc., 23 S.W.3d 389, 396 (Tex.App. — Amarillo 2000, no pet.) (misrepresentation). Because Plaintiffs have produced no evidence showing causation, an essential element of Plaintiffs’ case, Koenig’s personal injury claims fail as a matter of law. See Comm. Workers v. Ector County Mosp. Disk, 392 F.3d 733, 748 (5th Cir.2004) (stating that summary judgment is appropriáte where the evidence demonstrates that no genuine issues of material fact exist as to an essential, element of the non-moving party’s case).

B. Lack of Evidence on Causation

Plaintiffs have failed to raise a genuine issue of material fact as to causation because they have presented no evidence demonstrating a causal connection between Koenig’s prescriptions and Abbott’s co-promotion of OxyContin. Dr. Craig Danshaw (“Dr.Danshaw”) first prescribed OxyContin to Koenig in September 1999, for one month, and then resumed prescribing OxyContin to Koenig from May 2000 until September 2002. It is undisputed that Abbott did not contact Dr. Danshaw to promote OxyContin until August 2001, nearly two years after Dr. Danshaw first prescribed OxyContin to Koenig. Because Abbott did not contact Dr. Danshaw until after he began prescribing OxyContin to Koenig, it cannot be said that Abbott’s co-promotion of OxyContin caused Dr. Dan-shaw to prescribe OxyContin to Koenig, or that Abbott caused any of Plaintiffs’ personal injuries.

Dr. Alex Tseng (“Dr.Tseng”) also prescribed OxyContin to Koenig on just one occasion in June 2002, during the time that Dr. Danshaw was Koenig’s primary prescribing physician. Koenig testified in deposition that he took only one of the pills prescribed by Dr. Tseng and then resumed receiving his prescriptions from Dr. Dan-shaw. Although Abbott conducted promotional visits with Dr. Tseng beginning in February of 2002, there is no evidence that Dr. Tseng prescribed OxyContin for any reason other than to maintain Dr. Dan-shaw’s treatment regimen, which began in May of 2000. In short, Plaintiffs have produced no evidence showing that Abbott caused Dr. Danshaw or Dr. Tseng to prescribe OxyContin for Koenig. Because Plaintiffs have not demonstrated a genuine fact issue on the essential element of causation, the Court GRANTS summary judgment for Abbott on Koenig’s personal injury claims.

IV. Plaintiffs’ Personal Injury Claims Against Purdue — Learned Intermediary

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McKay v. Novartis Pharmaceuticals Corp.
934 F. Supp. 2d 898 (W.D. Texas, 2013)
Solomon v. Bristol-Myers Squibb Co.
916 F. Supp. 2d 556 (D. New Jersey, 2013)
Centocor, Inc. v. Hamilton
372 S.W.3d 140 (Texas Supreme Court, 2012)
Downing v. Hyland Pharmacy
2008 UT 65 (Utah Supreme Court, 2008)
Ackermann v. Wyeth Pharmaceuticals
526 F.3d 203 (Fifth Circuit, 2008)
Ebel v. Eli Lilly and Co.
536 F. Supp. 2d 767 (S.D. Texas, 2008)
United States v. Purdue Frederick Co., Inc.
495 F. Supp. 2d 569 (W.D. Virginia, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
435 F. Supp. 2d 551, 2006 U.S. Dist. LEXIS 38412, 2006 WL 1489250, Counsel Stack Legal Research, https://law.counselstack.com/opinion/koenig-v-purdue-pharma-co-txnd-2006.